Latham & Watkins

Eveline Van Keymeulen is a partner in Latham & Watkins' Brussels and Paris offices and Global Vice Chair of Latham & Watkins' Healthcare & Life Sciences Practice.

She advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food and beverage sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations, and general compliance matters.

In addition, Eveline has extensive experience advising on cannabis and hemp-based product regulations. She successfully challenged the legality of French hemp regulations in the first landmark case related to cannabidiol (CBD) products before the Court of Justice of the European Union (Case C-663/18, Kanavape). This transaction won the Creating New Standards award at the Financial Times European Innovative Lawyer Awards 2022.

Eveline has authored numerous articles and has been a featured speaker on EU regulatory matters at prominent conferences such as the Pharmaceutical Law Academy in Cambridge. She also serves on the editorial board of the European Pharmaceutical Law Review.

In addition, Eveline has been quoted in BBC Business Daily, Bloomberg, The Times, Les Echos, and other leading international business journals on life sciences regulatory and policy matters.